GLP1R and obesity due to melanocortin 4 receptor deficiency: These results are not surprising, given that the role of semaglutide and other GLP-1 analogues in reducing appetite, calorie intake, and consummatory behaviors has been well documented — factors that contributed to semaglutide’s approval for the treatment of obesity (69).